Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Sahlgrenska University Hospital
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
Revolution Medicines, Inc.
Arbeitsgemeinschaft medikamentoese Tumortherapie
The Christie NHS Foundation Trust
UNICANCER
UNC Lineberger Comprehensive Cancer Center
RAPT Therapeutics, Inc.
UNICANCER
AstraZeneca
University of Maryland, College Park
UNC Lineberger Comprehensive Cancer Center
DxTerity Diagnostics
Xencor, Inc.
National Institutes of Health Clinical Center (CC)
University of Maryland, College Park
Institut de cancérologie Strasbourg Europe
Corvus Pharmaceuticals, Inc.
Barbara Ann Karmanos Cancer Institute
Klus Pharma Inc.
Revolution Medicines, Inc.
Fate Therapeutics
Xencor, Inc.
National Institutes of Health Clinical Center (CC)
Quadriga Biosciences, Inc.
Xencor, Inc.
Ludwig Institute for Cancer Research
University Health Network, Toronto
Incyte Corporation
Technische Universität Dresden
Augusta University
Pfizer
National Institutes of Health Clinical Center (CC)
MacroGenics
Seagen Inc.
Incyte Corporation
Seagen Inc.
Wake Forest University Health Sciences
Institut de Cancérologie de Lorraine
Gilead Sciences
Institut Cancerologie de l'Ouest
Seagen Inc.
Rutgers, The State University of New Jersey